-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $30

Benzinga·01/08/2026 14:50:56
Listen to the news
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $22 to $30.